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Abstract
Objective: Rheumatoid arthritis (RA) differs depending on the age of disease onset. The differences between EORA and YORA are 
important because they have clinical and therapeutic implications.
Method: 1185 patients were ranked after classification according to age at onset of the disease into YORA I (16–40 years), YORA II 
(41–60 years) and EORA .60 years. All patients groups were compared, based on disease duration, disease activity, severity   parameters 
and drug history.
Results: YORA I included 298 patients, 28.85% were males, with mean age of 29.4 ± 6 years and disease duration 4 ± 3.3 y, YORA II 
included 539 patients, 33.77% males, age 49.7 ± 6.1 y and disease duration 6.5 ± 5.6 y. EORA included 348 RA patients 40.5% males, 
age 67.1 ± 6.6 y, disease duration 9.95 ± 7.2 y. Activity was increased in EORA compared to YORA I and YORA II, while severity 
decreased in EORA. ESR, CRP and degree of anemia were higher in EORA. RF titer was higher in YORA. Small joints of the hands 
and feet were more involved in YORA, while, large joints in EORA.
Rheumatoid nodules were increased in YORA I than EORA P = 0.04. Polymyalgia rheumatica was exclusively present in EORA group 
25 patients 7.2%.
Methotrexate was used in both YORA and EORA, with a higher mean of dosage in YORA than EORA. Multiple DMARDs in EORA 
was 57.9%, and biologics in 0.8% was which was significantly lower compared with YORA I, 86.3% and 1.7%, with P = 0.001.
Conclusion: EORA has more active and less disabling and affects more males than YORA. The use of biologic therapy and   combination 
DMARD therapy was less in EORA.
Keywords: EORA, YORA, Egypt. Age of onset elderly patients, young onset, DMARDs, Methotrexate, DAS 28, HAQ, rheumatoid 
arthritis, treatment, biological treatment, registryel-Labban et al
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Introduction
Rheumatoid arthritis (RA) is a chronic destructive 
inflammatory disease characterized especially by the 
involvement of small joints.1 RA usually develops in 
middle aged adults; however, it may occur at child-
hood or old age, too.2 RA is known to increase in 
incidence and prevalence up to approximately age of 
85 years. The presentation, severity and prognosis of 
RA differ depending on the age of disease onset. The 
prevalence of RA in 60 years of age and older persons 
is reported to be around 2%.1 The issue of whether 
RA arising in the elderly population (EORA) is a dis-
tinct disease from younger onset RA (YORA) is not 
settled yet. A major concern is that arthritic disorders 
and functional status may diminish elderly patients’   
independence. Despite several cross-sectional stud-
ies, it has not been clearly established if there are 
important clinical differences between elderly onset 
rheumatoid arthritis (EORA) and younger onset rheu-
matoid arthritis (YORA).3
This study was conducted to analyze and compare 
the demographic data, clinical profiles, disease activ-
ity and different treatment modalities in patients with 
elderly onset RA (EORA) and younger onset rheu-
matoid arthritis (YORA). We conducted this study 
utilizing the registry, and database generated by rheu-
matologist investigators of the rheumatology service 
at  Minia  University  hospital  (a  hospital  serving  a 
whole region of Minia governorate), Egypt.
Patients and method
Data  of  1185  RA  patients  who  fulfill  the  ACR 
  classification  criteria  of  RA,4  were  reviewed,  in  a 
  retrospective study including clinical, functional, lab-
oratory and radiological assessments. All RA patients 
were classified according to the age at onset of the RA 
  disease into:
•  YORA I: with onset between 16–40 years.
•  YORA II: with disease onset between 41–60 years.
•  EORA: with disease onset .60 years.
All  patients  were  compared,  based  on  disease 
  duration, disease activity and severity parameters and 
the proportion of patients on methotrexate, multiple 
disease modifying anti-rheumatic drugs (DMARDs), 
and biologic agents in each group. The Ritchie   articular 
index (RAI),5 tender joint count (TJC), swollen joint 
count  (SJC),  and  disease  activity  score  (DAS  28) 
were used as a parameters of disease   activity.6 Joint 
erosions were used as markers of disease severity and 
damage. Disability was assessed using the Stanford 
Health  Assessment  Questionnaire  disability  index 
(HAQ DI).7
statistical analysis
Data were expressed as the mean ± SD for baseline 
measurement. The Data were analyzed by the Statis-
tical Package for the Social Sciences (SPSS, version 
11.0 under windows).8 One-way analysis of variance 
was used. A two-tailed P value less than 0.05 was 
considered significant.
Results
The  number  of  RA  patients  in YORA  I  was  298, 
28.85% of them were males, mean (age 29.4 ± 6 and 
disease duration 4 ± 3.3 years),YORA II were 539 
patients with 33.77% males, mean (age 49.7 ± 6.1 y 
and disease duration 6.5 ± 5.6 y) and EORA were 348 
patients with 40.5% males, mean (age 67.1 ± 6.6 y and 
disease duration 9.95 ± 7.2 y) are shown in (Table 1 
and Fig. 1). Frequency and pattern of joint involve-
ment  in  YORA  and  EORA  groups  are  shown  in 
Table 2 in which peripheral small joints of the hands 
and feet were mainly involved in YORA groups while 
Table I. Patient characteristics.





























Disease duration 4 ± 3.3 Y 6.5 ± 5.6 Y 9.95 ± 3.2 Y 0.003** & 0.01*YOrA and eOrA among rA egyptian patients
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Table 2. Frequency of joint involvement in YOrA and eOrA.
parameters YORA I (16–40) Y 
n = 298
YORA II (41–60) Y 
n = 539
eORA .60 Y 
n = 348
P value
PIP 224 (75.1) 346 (64.2) 152 (43.7) ,0.001 & 0.02
MCP 266 (89.3) 391 (72.6) 189 (54.4) ,0.001 & 0.01
Wrist 223 (74.7) 371 (68.9) 227 (65.3) 0.04 & ns
elbow 115 (38.5) 168 (31.2) 97 (27.8) 0.005 & 0.04
shoulder 11 (3.7) 46 (8.6) 65 (18.7) ,0.001 & 0.006
MTP 50 (16.7) 51 (9.4) 29 (8.4) 0.022 & ns
Ankle 159 (53.3) 232 (43) 98 (28.1) ,0.01 & 0.03
Knee 190 (63.8) 340 (63.1) 253 (72.6) ns










Figure 1. number and percentage of patients in different rA groups.
large joints were involved in EORA group more than 
in YORA groups (Table 2). Extra-articular features 
of YORA and EORA are shown in Table 3a, where 
rheumatoid nodules were present in 15% of YORA I, 
14% of YORA II and 6.8% of EORA with a signifi-
cant increase in YORA I compared with EORA where 
P value = 0.04, where Polymyalgia rheumatica like 
symptoms (PMR) was exclusively present in EORA 
group 25 patients (7.2%). Comorbidities and common 
joint deformities in both EORA and YORA groups 
are shown in Table 3b.
Disease  activity  and  severity  differed  slightly 
between YORA I and YORA II, but disease activ-
ity  was  increased  in  EORA  compared  to  both 
YORA  I  and YORA  II, The  mean  of  tender  joint 
count (TJC) was 6.2 ± 2.8 in YORA I, 8.3 ± 4.1 in 
YORA  II  and  9.2  ±  3.9  in  EORA  with  a  signifi-
cant  statistical    difference  between  YORA  I  and 
EORA where P value = 0.01. Ritchie articular index 
(RAI) mean was 16 ± 5 in YORA I, 20.4 ± 3.8 in 
YORA II and 21.8 ± 4.1 in EORA with a signifi-
cant  statistical  difference  between  YORA  I  and 
EORA where P value = 0.04. Swollen joint count 
(SJC) was 5.7 ± 3.9 in YORA I, 6.8 ± 4.6 in YORA 
II and 8.1 ± 3.7 in EORA with a significant statis-
tical difference between YORA I and EORA where 
P value = 0.01. DAS-28 was 3.6 ± 2.6 in YORA I, 
3.9 ± 1.8 in YORA II; and 4.3 ± 2.3 in EORA with 
a significant statistical difference between YORA I 
vs. YORA II and EORA where P value was 0.03 and 
0.05 respectively. Patient visual analogue scale for 
pain (VAS) was 26.8 ± 9.3 in YORA I, 28.12 ± 7.1 in 
YORA II; and 36.0 ± 13.2 in EORA with a signifi-
cant statistical difference between YORA I vs. EORA 
where P value was 0.04. Patient Global Assessment 
was 15.7 ± 18.3 in YORA I, 20.9 ± 13.6 in YORA II; 
and 32.5 ± 14. 8 in EORA with a significant statistical 
difference between YORA I vs. YORA II and EORA 
where P value was 0.001 and 0.007 respectively. Phy-
sician Global assessment was 16.5 ± 11.2 in YORA I, 
23.7 ±  9.3 in YORA II; and 29.5 ± 14.6 in EORA with 
a significant statistical difference between YORA I 
vs. YORA II and EORA where P value was 0.002 
and 0.04 respectively (Table 4).
While disease severity decreased in EORA com-
pared to Both YORA I and II for example: Joint ero-
sions were present in 94 (39.6%) of YORA I, 193 
(35.8%) in YORA II and in 118 (27.01%) of EORA 
patients (Table 5). HAQ disability index (HAQ DI) 
was 0.34 in YORA I, 0.28 in YORA II, and 0.26 in 
EORA, with a significant statistical difference between 
YORA  I  vs.  YORA  II  and  EORA  groups  where 
P value = 0.003 and 0.01 respectively ( Table 6).el-Labban et al
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Table 3b. Common co-morbidities and join deformities in YOrA and eOrA.







sjogren’s syndrome 27 (9.0) 65 (12) 15 (4.3) ,0.04 & 0.01
Interstitial lung disease 39 (13) 43 (8) 21 (6) 0.01 & 0.03
Malignancy 3 (0.9) 11 (2.1) 13 (3.6) 0.03 & ns
swan-neck 158 (53.2) 127 (23.5) 64 (18.3) ,0.001 & ns
Ulnar deviation 270 (90.6) 403 (74.8) 191 (54.8) ,0.001 & 0.04
Boutonniere 140 (46.9) 156 (28.9) 62 (17.7) ,0.001 & 0.02
Table 3a. extra-articular features in YOrA and eOrA.







Loss of weight 60 (20.0) 149 (27.6) 136 (39) 0.01 & 0.04
Fever 33 (11) 809 (15) 59 (17) ns
Myalgia 11 (3.8) 29 (5.4) 37 (10.5) 0.003 & ns
Fatigue 217 (72.9) 433 (80.4) 295 (84.7) ns
Lymphadenopathy 17 (5.6) 25 (4.7) 73 (21) 0.02 & 0.003
hepatomegaly 19 (6.3) 48 (8.9) 35 (10.1) ns
splenomegaly 15 (5) 32 (6) 24 (7) ns
neuropathy 18 (5.9) 97 (18) 87 (25.0) ,0.001 & 0.05
rheumatoid nodules 45 (15) 75 (14) 24 (6.8) 0.04 & 0.05
PMr-like symptoms 0 0 25 (7.2) 0.001
Laboratory parameters including ESR, CRP and 
degree  of  anemia  were  significantly  increased  in 
EORA group compared to both YORA I and II, IgM 
Rheumatoid factor titer was significantly increased in 
YORA group compared to EORA group (Table 7).
Regarding therapy, methotrexate use was slightly 
more  common  among  YORA  patients  (89.3% 
YORA  I  vs.  83.6% YORA  II  vs.  58.4%  EORA), 
although the mean methotrexate dose among both 
YORA I and II was higher than EORA. The percent-
age of EORA patients who were on multiple DMARD 
therapy (57.9%) or on biologic agents (0.8%) was 
significantly lower compared with YORA I patients 
(86.3% and 1.7%, where P value = 0.001), (Table 8). 
Toxicity related to therapy was very minimal in both 
groups, while toxicities related to methotrexate and 
anti malarial drugs were more common in EORA 
group.
Discussion
Rheumatoid  arthritis  is  the  most  prevalent  inflam-
matory synovitis affecting 2%–2.3% of the geriatric 
population.9  Differential  diagnostic  possibilities  for 
EORA  are  PMR,  pseudo  gout,  reflex  sympathetic 
dystrophy and osteoarthritis which must be excluded 
before definite diagnosis of EORA.10 Since EORA is 
difficult to diagnose exactly, it takes a long time to be 
sure of the definite diagnosis. Meanwhile, we found 
that the disease duration was longer in EORA than in 
YORA (9.95 ± 3.2 y in EORA, 4 ± 3.3 y in YORA I, 
and 6.5 ± 5.6 y in YORA II, P = 0.003 and 0.01.
A  striking  female  preponderance  characterizes 
many autoimmune diseases and estrogen   activated 
humoral  immunity.  Sex  steroids  contribute  to  the 
expression of autoimmune diseases.11 It is well known 
that women are affected approximately three times 
as often as men, but gender differences have been 
diminishing in the studies of the older age group.2,12 
In our study, the gender ratio in EORA was similar 
to that in literature male:female (♂/♀) (1/4.8) (♂/♀ 
in EORA was 1/1.5, YORA I 1/2.5 and in YORA II 
1/2), but there was more preponderance of female 
involvement  in  YORA  groups  in  comparison  to 
EORA group with P value = 0.02 and 0.004. With 
regard to morning stiffness duration, Deal and his 
colleagues13 emphasized that there were no differ-
ences between EORA and YORA. However, Pease 
and his colleagues14 found that EORA patients had 
longer morning stiffness than that in YORA patients, 
and we found that EORA group had increase morn-YOrA and eOrA among rA egyptian patients
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ing  stiffness    duration  and  increase  in  the  disease 
activity  parameters  in  comparison  to  the  YORA 
groups.
In some papers, shoulder involvements in EORA 
are reported in 48%–64%; however, it was found in 
18.7% in our study, which was statistically higher 
than that in YORA 3.7% with P = 0.001. More sig-
nificant and frequent shoulder joint involvements in 
EORA group may testify to the concomitant degener-
ative-destructive changes of non-rheumatoid nature 
and  other  large  joints  are  involved  in  the  EORA 
group  frequently.  Although  PIP,  MCP  (89.3%  in 
YORA I and 54.4% in EORA with P value = 0.001), 
elbow, MTP and ankle joints were more commonly 
involved in YORA than in EORA. Classical rheu-
matoid  hand  deformities,  interstitial  lung  disease 
and SS were significantly lower in EORA patients 
than in YORA patients, whereas EORA patients had 
more common constitutional features such as weight 
loss  and  Myalgia,  Lymphadenopathy,  rheumatoid 
nodules and neuropathy, this was similar to that of 
Turkcapar et al.15
A substantial proportion of EORA patients had a 
PMR like symptoms including bilateral aching and 
prolonged morning stiffness involving neck or torso, 
shoulders or arms, hips or thighs, that occur in epi-
sodic attacks at different times during the patients 
follow  up.  The  occurrence  of  peripheral  arthritis 
particularly in both hands may lead to some difficul-
ties in the differential diagnosis between PMR and 
EORA. They had a different clinical condition from 
classical RA to a closely similar condition of PMR. 
A diagnosis of PMR or RA could therefore be made 
in the same patient at a different time depending on 
the clinical expression of the disease.16,17 Moreover, 
in other studies the patients were considered to have 
PMR,  manifesting  the  broader  clinical  spectrum 
of this disease at the end of the period of observa-
tion.18,19 In our study episodic attack of PMR-like 
symptoms, (that do not fulfill a complete picture of 
PMR) were found in 7.2% of EORA patients and 
it is similar to other studies.17,19,20 The large joint 
involvements especially of the shoulders are com-
mon  in  EORA  patients.  It  is  reported  that  older 
patients had an acute onset, in both small and large 
joint involvements and PMR-like symptoms more 
frequently.21
There are controversial results about RF sero-
positivity in EORA. It was found to be higher in 
EORA than in YORA (89% versus 78%) by Van 
der Heijde et al21 but we found RF seropositivi-
ties higher in YORA than in EORA, similar to that 
reported by other investigators.22–24 In our study, 
the frequencies of RF, ANA, anti-SSA/Ro and anti-
SSB/La seropositivities were lower in EORA than 
in YORA, but anemia-associated chronic diseases, 
Table 5. Disease severity characteristics in patients sub groups.
parameter YORA I (16–40) Y 
n = 298
YORA II (41–60) Y 
n = 539
eORA .60 Y 
n = 348
number and % number and % number and %
X-ray  
bone erosions
(118) 39.6% 193 (35.8%) 94 (27.01%)
Table 4. Disease activity characteristics in rA patients sub groups.







M ± sD M ± sD M ± sD
Physician global assessment 16.5 ± 11.2 23.7 ± 9.3 29.5 ± 14.6 0.002 & 0.04
Patient global assessment 15.7 ± 18.3 20.9 ± 13.6 32.5 ± 14.8 0.001 & 0.007
Patient VAs (pain) 26.8 ± 9.3 28.12 ± 7.1 36.0 ± 13.2 0.04 & 0.06
sJC 5.7 ± 3.9 6.8 ± 4.6 8.1 ± 3.7 0.07 & 0.1
rAI 16 ± 5 20.4 ± 3.8 21.8 ± 4.1 0.04 & 0.07
TJC 6.2 ± 2.8 8.3 ± 4.1 9.2 ± 3.9 0.01 & 0.06
DAs 28 3.6 ± 2.6 3. 9 ± 1.8 4.3 ± 2.3 0.03 & 0.05el-Labban et al
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elevated  ESR  and  CRP  were  more  common  in 
EORA patients and these results are similar to the 
literature.14,22,25
Regarding  therapy;  (in  Table  8),  methotrex-
ate  use  was  slightly  more  common  among YORA 
patients (89.3% YORA I vs. 83.6.6% YORA II vs. 
58.4% EORA), although the mean methotrexate dose 
among both YORA I and II was higher than EORA. 
The percentage of EORA patients who were on mul-
tiple DMARD therapy (57.9%) or on biologic agents 
(0.8%) was significantly lower compared with YORA I 
patients (86.3% and 1.7%, where P value = 0.001). 
Toxicity related to therapy was very minimal in both 
groups, while toxicities related to methotrexate and 
anti  malarial  drugs  were  more  common  in  EORA 
group.
This study demonstrates that EORA group has 
more active and less disabling disease course and 
affects more males than YORA groups. Erosions 
were more prevalent in YORA groups than EORA 
and also HAQ disability index increased in YORA 
compared  to  EORA.  Peripheral  small  joints  of 
the hands and feet were significantly involved in 
YORA I and II compared to EORA, which decrease 
the  self  care  activities  of  the  YORA  groups, 
hence increase the HAQ score, while Para axial large 
joints were involved more frequently in EORA than 
YORA. IgM Rheumatoid factor titer was increased 
in YORA group and associated with poor remis-
sion  in  EORA  group.    PMR-like    symptoms  were 
  exclusively present in EORA not in YORA groups, 
  However,  some  cases  with  negative  rheumatoid 
factor and   polymyalgia-like symptoms appear to be 
a distinct subset with a   different genetic basis and 
a more benign course.26 Joint deformities were sig-
nificantly high in YORA groups than EORA. The 
aging process is associated with important changes 
in drug pharmacokinetics and pharmacodynamics. 
It appears that the former, mainly through decreased 
renal clearance, is responsible for an increased inci-
dence of adverse effects with some DMARDs.27 In 
our patients the use of biologic therapy and combi-
nation DMARD therapy were less frequently used 
in  EORA  than  in YORA  patients  because  of  the 
  presence of co-morbidities and financial aspects in 
this group of patients. Taking the age at onset into 
consideration,  these  differences  must  be  kept  in 
mind  while  making  RA  diagnosis  which  may  be 
of benefit not only in providing the correct diag-
nosis  but  also  of  its  prognostic  and  therapeutic 
implications.
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Table 7. The laboratory features of YOrA I and II and eOrA patients.
parameters YORA I (16–40) Y 
n = 298
YORA II (41–60) Y 
n = 539
eORA .60 Y 
n = 348
P value
esr 53.3 ± 9.5 73.8 ± 16.6 94 ± 32.3 0.004 & 0.02
CrP 18.5 ± 3.6 24.5 ± 12.7 48.12 ± 6.7 0.001 & 0.01
hB 9.6 ± 3.6 10.4 ± 2.9 11.3 ± 3.7  0.01 & 0.06
Ig M rF 72.7 ± 8.4 56.9 ± 16.5 32.13 ± 8.5 0.002 & 0.03
AnA 157 ± 90.8 90.5 ± 60.3 70.6 ± 34.7 0.04 & 0.2
Table 6. Disability assessment in rA patients sub groups.
Age at onset of RA
parameter YORA I (16–40) Y 
n = 298
YORA II (41–60) Y 
n = 539
eORA .60 Y 
n = 348
P value
M ± sD M ± sD M ± sD
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Table 8. Types-of treatment in rA sub groups.
Age at onset of RA
parameter YORA I (16–40) Y 
n = 298
YORA II (41–60) Y 
n = 539
eORA .60 Y 
n = 348
MeTXOTreXATe 







Multiple DMArDs 257 (86.3%) 427 (79.3%) 201 (57.9%)
steroids 78 (26.2%) 123 (22.8%) 112 (32.2%)
Biologic therapy 5 (1.7%) 12 (2.3%) 3 (0.8%)